

List of Figures

Figure No.	Figure Captions	Page No.
1.1	Drug Development Process	2
1.2	Differences between composition of mammalian and bacterial cell membranes	4
1.3	Benzothiazole, a multifunctional nucleus	9
1.4	Chemical structures of pharmacologically relevant benzothiazoles	10
1.5	Chemical structures of biologically important benzothiazole compounds	10
1.6	Drugs containing benzothiazole nucleus	11
1.7	Chemical structures of benzothiazole derivatives with anticancer properties	13
1.8	Chemical structures of benzothiazole derivatives with antimicrobial properties	14
1.9	Multiple targets of antibiotics	15
1.10	Targeted therapy for anticancer agents	16
2.1	Mode of action of Phortress	31
2.2	Structure-activity relationship of benzothiazole scaffold	34
2.3	Numbering tautomerism in benzothiazole	35
2.4	Biological Assembly Image for Glucosamine 6-phosphate synthase with Glucose 6-phosphate (1JXA)	44
2.5	EGFR signaling pathways: Signaling pathways and epidermal growth factor tyrosine kinase receptors involved in the tumorigenesis of NSCLC.	46
3.1	Rationale of approach	48
3.2	Design of benzothiazole derivatives	50
4.1	Proposed reaction mechanism of formation of benzothiazole-amide ring system	56

4.2	Proposed reaction mechanism of formation of benzothiazole-semicarbazone/ thiosemicarbazone ring system	60
5.1	Comparative zone of inhibition of compounds S02 , S08 , S13 , S15 and S19 against all the bacterial strains	83
5.2	Time dependent killing of (A) <i>S. aureus</i> (B) <i>E. coli</i> upon treatment with compounds S08 and S15 at 4 × MIC	84
5.3	Membrane depolarization ability of designed compounds on (A) <i>E. coli</i> and (B) <i>S. aureus</i> treated with 4xMIC concentration of compounds S08 and S15 .	85
5.4	Determination of compound-induced membrane damage of <i>S. aureus</i> and <i>E. coli</i> cells. (A–F) PI staining of <i>S. aureus</i> (A) control without PI treatment (B) S08 (C) S15 and on <i>E. coli</i> (D) control without PI treatment (E) S08 (F) S15 , respectively.	86
5.5	Agarose gel electrophoresis patterns of pUC19 (200 ng) cleaved by (A) S08 (B) S15 .	87
5.6	Agarose gel electrophoresis pattern for the cleavage of supercoiled DNA (200ng) by compound S15 in the presence of DAPI and Methyl Green.	87
5.7	Binding pose of compound (A) S13 (B) S19 (C) Ciprofloxacin and (D) Fluconazole with glucosamine-6-phosphate synthase.	89
5.8	Effect of different concentrations (1mM, 0.1mM and 0.01mM) of compounds S05 , S02 , S01 , S11 and S13 on viability of ovarian cancer cell lines (A2780 and SKOV3)	94
5.9	Effect of concentration (1mM – 1nM) of compounds S05 and S02 on viability of human ovarian cancer SKOV3 cell line	94
5.10	Effect of concentration (1mM – 1nM) of compounds S05 and S02 on viability of human ovarian cancer A2780 cell line	95
5.11	Effect of concentration (1mM – 1nM) of compound S05 on viability of human ovarian cancer A2780-CR cell line	95
5.12	Growth inhibitory effect of compound S05 on (A) A2780-S (B) A2780-CR and A2780-PR cell lines	96
5.13	Growth inhibitory effect of compound S05 on viability of normal ovarian cancer surface epithelial cell line (IOSE 364)	96
5.14	Growth inhibitory effect of compound S05 as a combinatorial	97

	treatment on (A) A2780-CR (B) A2780-PR cell lines	
5.15	Proposed hypothetical model of the highly active (S05) bound to ATP binding site of EGFR Protein tyrosine kinase	99
5.16	Predicted binding pose of compound S01 at the ATP-binding site of EGFR-TK	100
5.17	(A) Predicted binding pose of compound S05 at the ATP-binding site of EGFR (B) Hydrophobic surface regions of EGFR kinase domain. (C) Electrostatic potential regions over molecule S05	102
5.18	Immunoblot analysis of the EGFR in ovarian cancer cell lines (a) SKOV3 (b) A2780-S and (c) A2780-CR.	107
5.19	Time dependent killing of (A) <i>S. aureus</i> (B) <i>E. coli</i> upon treatment with compounds A07 and A10 at $4 \times \text{MIC}$	117
5.20	Membrane depolarization ability of designed compounds on (A) <i>E. coli</i> and (B) <i>S. aureus</i> treated with $4x\text{MIC}$ concentration of compounds A07 and A10	118
5.21	Determination of compound-induced membrane damage of <i>E. coli</i> and <i>S. aureus</i> cells by flow cytometric studies. (A–H) PI staining of <i>E. coli</i> (A) control without PI treatment (B) control with PI treatment (C) A07 (D) A10 and on <i>S. aureus</i> (E) control without PI treatment (F) control with PI treatment (G) A07 (H) A10 , respectively	119
5.22	Agarose gel electrophoresis patterns of pUC19 (200 ng) cleaved by (A) A07 and (b) A10	120
5.23	Agarose gel electrophoresis pattern for the cleavage of supercoiled DNA (200 ng) by A07 in presence of DAPI and methyl green.	121
5.24	Binding pose of compound A10 with glucosamine-6-phosphate synthase. Hydrogen bonding interactions are displayed by green dotted lines	121
5.25	Effect of the lead compounds (A) A01 (B) A03 (C) A07 and (D) A08 on SiHa and C33-A cell growth.	125
5.26	Comparative IC_{50} values of compounds (A01-A10) against SiHa and C33-A cell lines	125
5.27	Micrographs of the control and compounds (A01-A10) treated SiHa cells.	126
5.28	Micrographs of the control and compounds (A01-A10) treated C33-A cells.	126

5.29	Percentage cytotoxicity of HEK-293, a normal epithelial cell line at various concentrations (10–50 μ M) of compounds A01 , A03 , A07 and A08	127
5.30	Flow cytometric analysis of the effect of the compounds (A01-A10) on the cellular DNA content of SiHa cells.	128
5.31	Flow cytometric analysis of the effect of the compounds (A01-A10) on the cellular DNA content of C33-A cells.	129
5.32	Flow cytometric analysis for the cell cycle distribution of (A) SiHa and (B) C33-A cells after exposure to compounds A01 , A03 , A07 and A08 for 48 h	129
5.33	SiHa cells treated with compounds (A01-A10) at their respective IC_{50} s for 48 h were analyzed using AnnexinV-AlexaFlour488/PI flow cytometry.	131
5.34	C33-A cells treated with compounds (A01-A10) at their respective IC_{50} s for 48 h were analyzed using AnnexinV-AlexaFlour488/PI flow cytometry.	132
5.35	DNA fragmentation of SiHa cells exposed to the compounds (A01-A10).	133
5.36	DNA fragmentation of C33-A cells exposed to the compounds (A01-10).	134
5.37	Time dependent killing of (A) <i>S. aureus</i> (B) <i>E. coli</i> upon treatment with compounds TB03 and TB07 at $4 \times$ MIC	143
5.38	Membrane depolarization ability of designed compounds TB03 and TB07 on (A) <i>E. coli</i> and (B) <i>S. aureus</i> .	144
5.39	Determination of compound-induced membrane damage of <i>S. aureus</i> and <i>E. coli</i> cells. (A–F) PI staining of <i>S. aureus</i> (A) control without PI treatment (B) TB03 (C) TB07 and on <i>E. coli</i> (D) control without PI treatment (E) TB03 (F) TB07 , respectively.	145
5.40	Agarose gel electrophoresis patterns of plasmid DNA (200 ng) cleaved by (A) TB03 and (B) TB07 .	146
5.41	Binding pose of compound (A) TB01 and (B) TB06 with glucosamine-6-phosphate synthase.	147
5.42	Bactericidal kinetics of (A) <i>S. aureus</i> (B) <i>E. coli</i> after treatment with test compounds A07a and A07b at $4 \times$ MIC	153

5.43	Membrane depolarization aptitude of test compounds A07a and A07b at $4 \times$ MIC on (A) <i>S. aureus</i> and (B) <i>E. coli</i> .	154
5.44	Fluorescence assisted cell sorting (FACS) data of <i>E. coli</i> and <i>S. aureus</i> (A–F). On <i>E. coli</i> (A) control without PI treatment (B) A07a (C) A07b and, on <i>S. aureus</i> (D) control without PI treatment (E) A07a (F) A07b , respectively.	155
5.45	DNA binding Agarose gel electrophoresis represents (A) A07a and (B) A07b , in concentration range: 31.2–3.91 μ g/ml.	156
5.46	Binding pose of compound (A) A07a and (B) A07b with glucosamine-6-phosphate synthase	157
5.47	Time dependent killing of (A) <i>S. aureus</i> (B) <i>E. coli</i> upon treatment with compounds SC06 , SC09 , TS05 and TS07 at $4 \times$ MIC concentrations	172
5.48	Membrane depolarization ability of designed compounds on (A) <i>S. aureus</i> and (B) <i>E. coli</i> treated with 4xMIC concentration of compounds TS05 , SC06 , TS07 and SC09 .	174
5.49	Bar diagram showing relative percentage fluorescence of (A) <i>S. aureus</i> and (B) <i>E. coli</i> of compounds TS05 , SC06 , TS07 , SC09 and Valinomycin.	174
5.50	Determination of compound-induced membrane damage of (I) <i>S. aureus</i> and (II) <i>E. coli</i> cells by flow cytometric studies. (A–F) PI staining of both strains (A) control without PI treatment (B) control with PI treatment (C) SC06 (D) SC09 (E) TS05 and (F) TS07 .	176
5.51	Agarose gel electrophoresis patterns of pUC19 (200 ng) cleaved by (A) SC06 (B) SC09 (C) TS05 (D) TS07 in the range of 31.2–3.91 μ g/ml.	178
5.52	Agarose gel electrophoresis pattern for the cleavage of supercoiled DNA (200 ng) by TS05 , TS07 and SC09 in presence of DAPI and MG.	178
5.53	Binding pose of compound (A) SC02 , (B) SC04 , (C) SC08 and (D) SC09 with glucosamine-6-phosphate synthase.	182
5.54	Binding pose of compound (A) TS05 , (B) TS06 and (C) TS08 with glucosamine-6-phosphate synthase	183
